Doping in Sport: New Developments

• Authors: Katarzyna Krych , Anna Goździcka-Józefiak
• Languages of publication: EN

Abstracts

EN

Gene doping is defined by the World Anti-Doping Agency (WADA) as "the non-therapeutic use of genes, genetic elements and/or cells that have the capacity to enhance athletic performance." The rapid development of molecular biology has enabled not only treatment of many diseases, but also improvement of athletes' fitness. Gene therapy methods can be used to modify the athlete's body by inserting genes into the target tissue. It is very possible that in near future, many genes will be used in gene doping, e.g. erythropoietin, growth hormone, insulin-like growth hormone and vascular endothelial growth factor. Functional tests conducted by many independent laboratories proved that products of these genes exert a crucial influence on the body's adaptation to exercise. The risk of gene doping is enormous. Gene therapy is currently in the phase of clinical tests so it is impossible to predict what kind of side effects it may produce. Studies on animal models showed that the uncontrolled transgene expression and insertional mutagenesis can even lead to death. At present the detection of gene doping is very difficult for a variety of reasons. The main problem is the identification of the transgene and endogenously produced protein. The only possible detection is the biopsy of the target tissue, where the exogenous genes were inserted.

Keywords

EN

gene doping; performance enhancement; gene transfer; doping detection

• Publisher: De Gruyter Open
• Journal: Human Movement
• Year: 2008
• Volume: 9
• Issue: 1
• Pages: 62-75

Dates

published

1 - 6 - 2008

online

23 - 6 - 2008

Contributors

author

Katarzyna Krych

• Department of Biology and Environmental Protection, University School of Physical Education, Poznań, Poland

author

Anna Goździcka-Józefiak

• Department of Molecular Virology, Adam Mickiewicz University, Poznań, Poland

References

• Verroken M., Drug use and abuse in sport. Best Pract Res Clin Endocrinol Metab, 2000, 14(1), 1-23. DOI: 10.1053/beem.2000.0050.[Crossref]
• Shatzman A. R., Expression systems. Curr Opin Biotechnol, 1995, 6(5), 491-493. DOI: 10.1016/0958-1669(95)80081-6.[Crossref]
• Szala S., Gene therapy [in Polish] (Gene Therapy). PWN, Warszawa 2003.
• Ehrnborg C., Bengtsson B-A., Rosen T., Growth hormone abuse. Best Pract Res Clin Endocrinol Metab, 2000, 14(1), 71-77. DOI: 10.1053/beem.2000.0054.[Crossref]
• Sonksen P. H., Insulin, growth hormone and sport. J Endocrinol, 2001, 170(1), 13-25. DOI: 10.1677/joe.0.1700013.[Crossref][PubMed]
• Humbel R. E., Insulin-like growth factors I and II. Eur J Biochem, 1990, 190(3), 445-462. DOI: 10.1111/j.1432-1033.1990.tb15595.x.[Crossref][PubMed]
• Frystyk J., Free insulin-like growth factors - measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res, 2004, 14(5), 337-375. DOI: 10.1016/j.ghir.2004.06.001[Crossref][PubMed]
• Massicotte F., Fernandes J. C., Martel-Pelletier J., Pelletier J-P., Lajeunesse D., Modulation of insulin-like growth factor 1 levels in human osteoarthritic subchondral bone osteoblasts. Bone, 2006, 38(3), 333-341. DOI: 10.1016/j.bone.2005.09.007.[Crossref]
• Kędzia A., Diagnostics of growth disorders and possibilities of treatment of short-stature children and adolescents in Wielkopolska. [in Polish] Adam Mickiewicz University Press, Poznań 2004.
• De Palo E. F., Gatti R., Lancerin F., Cappellin E., De Palo C. B., Spinella P., Urinary insulin-like growth factor-I measurement in an actual sport competition, an additional approach in laboratory antidoping tests. Clin Chim Acta, 2005, 351(1-2), 73-78. DOI: 10.1016/j.cccn.2004.06.023.[Crossref]
• Hameed M., Lange K. H. W., Andersen J. L., Schjerling P., Kjaer M., Harridge S. D. R. et al., The effect of recombinant human growth hormone and resistance training on IGF-I mRNA expression in the muscles of elderly men. J Physiol, 2004, 555(1), 231-240. DOI: 10.1113/jphysiol.2003.051722.[Crossref]
• Holt R. I. G., Simpson H. L., Sönksen P. H., The role of the growth hormone-insulin-like growth factor axis in glucose homeostasis. Diabet Med, 2003, 20(1), 3-15. DOI: 10.1046/j.1464-5491.2003.00827.x.[Crossref][PubMed]
• Lasne F., Martin L., De Ceaurriz J., Larcher T., Moullier P., Chenuaud P., "Genetic Doping" with erythropoietin cDNA in primate muscle is detectable. Mol Ther, 2004, 10, 409-410. DOI: 10.1016/j.ymthe.2004.07.024.[Crossref]
• Verbruggen H., The EPO epidemic in sport. Bloodline Reviews, Volume 3, Issue 2 (October 2005). Available from: http://static.cjp.com/gems/blood/BLR13.pdf.
• Breymann C., Erythropoietin test methods. Best Pract Res Clin Endocrinol Metab, 2000, 14(1), 135-145. DOI: 10.1053/beem.2000.0059.[Crossref]
• Lippi G., Franchini M., Guidi G., Second generation blood tests to detect erythropoietin abuse by athletes: Effective but not preventive? Haematologica, Volume 89, Issue 2 (2004). Available from: http://www.haematologica.org/cgi/reprint/89/4/ELT05.
• Yang N., MacArthur D. G., Gulbin J. P., Hahn A. G., Beggs A. H., Easteal S. et al., ACTN3 genotype is associated with human elite athletic performance. Am J Hum Genet, 2003, 73(3), 627-631.[PubMed][Crossref]
• Gayagay G., Yu B., Hambly B., Boston T., Hahn A., Celermajer D. S. et al., Elite endurance athletes and the ACE I allele - the role of genes in athletic performance. Hum Genet, 1998, 103(1), 48-50. DOI: 10.1007/s004390050781.[Crossref][PubMed]
• Lippi G., Guidi G. C., Gene manipulation and improvement of athletic performances: new strategies in blood doping. Br J Sports Med, 2004, 38, 641.
• Verma I. M., Doping, gene transfer and sport. Mol Ther, 2004, 10(3), 405. DOI: 10.1016/j.ymthe.2004.08.004.[PubMed][Crossref]
• Wang Y. X., Zhang C. L., Yu R. T., Cho H. K., Nelson M. C., Bayuga-Ocampo C. R. et al., Regulation of muscle fiber type and running endurance by PPAR delta. PLoS Biol, 2004, 2(10), 1532-1539.
• Unal M., Unal D. O., Gene doping in sports. Sports Med, 2004, 34(6), 357-362.[Crossref][PubMed]
• Bidlingmaier M., Wu Z., Strasburger C. J., Test method: GH. Best Pract Res Clin Endocrinol Metab, 2000, 14(1), 99-109. DOI: 10.1053/beem.2000.0057[Crossref]
• Sartorio A., Agosti F., Marazzi N., Trecate L., Silvestri G., Lafortuna C. et al., Gender-, age-, body composition- and training workload-dependent differences of GH response to a discipline-specific training session in elite athletes: a study on the field. J Endocrinol Invest, 2004, 27(2), 121-129.[PubMed]
• Wallace J. D., Cuneo R. C., Lundberg P. A., Rosen T., Jørgensen J. O. L., Longobardi S. et al., Responses of markers of bone and collagen turnover to exercise, growth hormone (GH) administration and GH withdrawal in trained adult males. J Clin Endocrinol Metab, 2000, 85(1), 124-133.[PubMed]
• Ehrnborg C., Lange K. H. W., Dall R., Christiansen J. S., Lundberg P.-A., Baxter R. C. et al., The growth hormone/insulin-like growth factor-I axis hormones and bone markers in elite athletes in response to a maximum exercise test. J Clin Endocrinol Metab, 2003, 88(1), 394-401.[Crossref][PubMed]
• Kicman A. T., Miell J. P., Teale J. D., Powrie J., Wood P. J., Laidler P. et al., Serum IGF-I and IGF binding proteins 2 and 3 as potential markers of doping with human GH. Clin Endocrinol, 1997, 47(1), 43-50. DOI: 10.1046/j.1365-2265.1997.2111036.x[Crossref]
• Azzazy H. M. E., Mansour M. M. H., Christenson R. H., Doping in the recombinant era: Strategies and countstrategies. Clin Biochem, 2005, 38(11), 959-965. DOI: 10.1016/j.clinbiochem.2005.09.007[PubMed][Crossref]
• Varlet-Marie, E., Audran, M., Lejeune, M., Bonafoux, B., Sicart, M. T., Marti, J. et al., Analysis of human reticulocyte genes reveals altered erythropoiesis: potential use to detect recombinant human erythropoietin doping. Haematologica, 2004, 89(8), 991-997.
• Ashenden, M. J., Gore, C. J., Parisotto, R., Sharpe, K., Hopkins, W. G., Hahn, A. G., Effect of altitude on second-generation blood tests to detect erythropoietin abuse by athletes. Haematologica, 2003, 88(9), 1053-1062.[PubMed]
• Ashenden, M., Varlet-Marie, E., Lasne, F., Audran, M., The effects of microdose recombinant human erythropoietin regimens in athletes. Haematologica, 2006, 91(8), 1143-1144.[PubMed]
• Scheinowitz M., Kessler-Icekson G., Freimann S., Zimmermann R., Schaper W., Golomb E. et al., Short- and long-term swimming exercise training increase myocardial insulin-like growth factor-I gene expression. Growth Horm IGF Res, 2003, 13(1), 19-25. DOI: 10.1016/S1096-6374(02)00137-5.[Crossref]
• Sweeney H. L., Gene Doping. Sci Am, 2004, 21, 63-69.
• Evans P. J., Lynch R. M., Insulin as a drug of abuse in body building. Br J Sports Med, 2003, 37, 356-357.
• Skibeli V., Nissen-Lie G., Torjesen P., Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood, 2001, 98(13), 3626-3634.[Crossref][PubMed]

Identifiers

DOI

10.2478/v10038-008-0009-4